Latest Breaking News On - Biovaxys or company - Page 1 : comparemela.com

BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE

/PRNewswire/ BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has received a Notice of Allowance.

United kingdomBritish columbiaUnited statesKenneth kovanSanofi pasteur fluzoneImv incPrnewswire biovaxys technology corpEuropean unionBiovaxys or companyTrademark officeBiovaxys technology corpVaxys technologyUnited states patentIntellectual propertyIntradermal quadrivalentWhereast cells

BioVaxys Technology Corp : BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC

BioVaxys Technology Corp : BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesBritish columbiaKenneth kovanBiovaxys or companyHorizon technology finance corporationPrnewswire biovaxys technology corpImmunovaccine technologies incBiovaxys technology corpVaxys technologyAsset purchase agreementCompanie creditors arrangement actBiovaxys presidentChief operating officer kenneth kovanRelapsed refractory diffuse largeb cell lymphomaFrankfurt bourse

BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC

VANCOUVER, BC, Feb. 21, 2024 /PRNewswire/ BioVaxys Technology Corp. is pleased to announce has completed the acquisition of the entire portfolio of discovery, preclinical and clinical.

United kingdomBritish columbiaUnited statesKenneth kovanBiovaxys or companyBiovaxys technology corpHorizon technology finance corporationPrnewswire biovaxys technology corpImmunovaccine technologies incVaxys technologyAsset purchase agreementCompanie creditors arrangement actBiovaxys presidentChief operating officer kenneth kovanRelapsed refractory diffuse largeb cell lymphomaFrankfurt bourse

Annual Financial Statements Update for the Year Ended October 31, 2023

/PRNewswire/ BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announces that as a result of delays in the.

United statesUnited kingdomBritish columbiaInternational accounting standards boardBiovaxys technology corpDale matheson carr hilton labonteNational instrumentBiovaxys or companyOntario securities commissionPrnewswire biovaxys technology corpVaxys technologyUnder national instrumentRequired filingsChief financial officerAsset purchase agreementReporting period

BioVaxys Technology Corp : Annual Financial Statements Update for the Year Ended October 31, 2023

BioVaxys Technology Corp : Annual Financial Statements Update for the Year Ended October 31, 2023
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesBritish columbiaPrnewswire biovaxys technology corpBiovaxys technology corpInternational accounting standards boardBiovaxys or companyDale matheson carr hilton labonteNational instrumentOntario securities commissionVaxys technologyUnder national instrumentRequired filingsChief financial officerAsset purchase agreementReporting period